0
0
A groundbreaking study led by researchers at the University of Cambridge has uncovered early immune cell changes in the breast tissue of carriers of BRCA1 and BRCA2 gene mutations, long before the onset of breast cancer. This discovery presents a promising opportunity for early intervention to prevent the disease, potentially offering an alternative to risk-reduction surgeries.
Individuals carrying BRCA1 and BRCA2 gene mutations face a significantly higher risk of developing breast and ovarian cancer. However, the study’s findings suggest that existing immunotherapy drugs, already approved for late-stage breast cancer treatment, could be repurposed to reactivate faulty immune cells in breast tissue and maintain cellular health, thus preventing cancer development.
The research, published in the journal Nature Genetics, marks a significant step towards understanding the mechanisms underlying breast cancer development and offers hope for new preventative strategies. Professor Walid Khaled, senior author of the report, expressed excitement about the discovery, emphasizing its potential to revolutionize breast cancer prevention.
The study involved the creation of the world’s largest catalogue of human breast cells, analyzing samples from 55 women to identify early cell changes associated with BRCA gene mutations. Researchers found signs of immune cell malfunction, termed ‘exhaustion,’ in the breast tissue of healthy BRCA mutation carriers. Importantly, these immune cell changes were detected long before the development of cancer, providing a window for intervention.
Dr. Sara Pensa, one of the study’s joint first authors, highlighted the importance of prevention, particularly in addressing social inequalities in access to treatment. By understanding the complex interactions between genetic and environmental risk factors, researchers aim to improve disease outcomes and reduce the global burden of breast cancer.
The findings have led to the initiation of a trial, funded by Cancer Research UK, to test the preventative approach in mice. If successful, the study could pave the way for clinical trials in human carriers of BRCA gene mutations, offering new hope for individuals at high risk of breast cancer.
While risk-reducing surgeries remain an option for some, they can pose significant emotional and physical challenges. The potential for preventative drug therapy represents a promising alternative, offering a less invasive and more accessible option for at-risk individuals.
As research continues to unravel the complexities of breast cancer development, studies like this provide valuable insights into new avenues for prevention and treatment. By leveraging existing drugs and understanding early immune cell changes, researchers aim to transform the landscape of breast cancer prevention, bringing hope to millions worldwide.
